公开(公告)号：US20240301092A1

公开(公告)日：2024-09-12

申请号：US18575016

申请日：2022-06-29

Applicant: TEGA Therapeutics, Inc.

Inventor： Bryan E. THACKER ,  Jeffrey D. ESKO ,  Charles A. GLASS

IPC: C08B37/00 ,  A61K31/727 ,  C08L5/10 ,  C12N5/00 ,  C12N5/0787 ,  C12N9/10

CPC classification number: C08B37/0075 ,  A61K31/727 ,  C08L5/10 ,  C12N5/0018 ,  C12N5/0642 ,  C12N9/13 ,  C12N2500/34 ,  C12N2510/02 ,  C12N2511/00

Abstract: Provided herein are methods of producing heparin and heparan sulfate from modified cells, such as modified MST cells, and compositions comprising heparin and heparan sulfate isolated from modified cells.

公开(公告)号：US20220305049A1

公开(公告)日：2022-09-29

申请号：US17638760

申请日：2020-08-27

Applicant: TEGA Therapeutics, Inc.

Inventor： Charles GLASS ,  Bryan THACKER ,  Jeffrey D. ESKO

IPC: A61K31/727 ,  A61P29/00 ,  A61P11/00 ,  A61P7/02 ,  C12N15/86 ,  C12N15/52 ,  C12N5/09 ,  C12P19/26

Abstract: Abstract: Provided herein are methods of producing heparin and heparan sulfate from modified cells, such as modified MST cells and modified basophil neoplastic cells, and compositions comprising heparin and heparan sulfate isolated from modified cells. In some embodiments, methods herein comprise culturing a genetically modified cell line comprising at least one of a mastocytoma cell line and a basophil neoplastic cell line; and isolating the heparin or heparan sulfate from the cell line.